Teladoc Health Inc.'s stock plummeted 5.07% during intraday trading on Thursday, reflecting investor concerns ahead of the company's upcoming first-quarter earnings report.
The decline follows an earnings preview indicating expected Q1 revenue of $611.38 million, a 1.26% year-over-year decrease, with forecast adjusted EPS of -$0.313 and EBIT loss of $53.73 million. Institutional commentary has been cautious to bearish, highlighting slowing enterprise demand, a tempered revenue outlook, and an elongated path to sustained profitability, which has dampened investor sentiment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments